Department of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA.
Booth School of Business, University of Chicago, Chicago, IL 60637, USA.
Int J Mol Sci. 2023 May 29;24(11):9429. doi: 10.3390/ijms24119429.
Targeted therapies have revolutionized the treatment for many patients with non-small cell lung cancer (NSCLC). Multiple new oral targeted therapies have been approved in the last decade; however, their overall efficacy may be reduced by poor adherence, treatment interruptions, or dose reductions due to adverse events. Most institutions lack standard monitoring protocols for toxicities from these targeted agents. This review describes important adverse events observed in clinical trials and reported by the U.S. Food and Drug Administration for both currently approved and upcoming promising therapies in the treatment of NSCLC. These agents cause a range of toxicities, including dermatologic, gastroenteric, pulmonary, and cardiac toxicities. This review proposes protocols for routine monitoring of these adverse events, both prior to initiation of therapy and while on treatment.
靶向治疗已经彻底改变了许多非小细胞肺癌（NSCLC）患者的治疗方法。在过去的十年中，已经批准了多种新的口服靶向治疗药物；然而，由于不良事件导致的药物依从性差、治疗中断或剂量减少，它们的总体疗效可能会降低。大多数机构缺乏针对这些靶向药物毒性的标准监测方案。本文综述了美国食品和药物管理局（FDA）在临床试验中观察到的，并报告了在 NSCLC 治疗中目前批准和即将推出的有前途的治疗药物的重要不良事件。这些药物会引起一系列的毒性反应，包括皮肤毒性、胃肠道毒性、肺部毒性和心脏毒性。本文提出了这些不良事件的常规监测方案，包括治疗前和治疗期间。
